Journal article

The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells

Z Wang, H Hu, L Heitink, K Rogers, Y You, T Tan, CLW Suen, A Garnham, H Chen, E Lieschke, ST Diepstraten, C Chang, T Chen, D Moujalled, K Sutherland, G Lessene, OM Sieber, J Visvader, GL Kelly, A Strasser

Cell Death and Differentiation | SPRINGERNATURE | Published : 2023

Abstract

Mutant TP53 proteins are thought to drive the development and sustained expansion of cancers at least in part through the loss of the wild-type (wt) TP53 tumour suppressive functions. Therefore, compounds that can restore wt TP53 functions in mutant TP53 proteins are expected to inhibit the expansion of tumours expressing mutant TP53. APR-246 has been reported to exert such effects in malignant cells and is currently undergoing clinical trials in several cancer types. However, there is evidence that APR-246 may also kill malignant cells that do not express mutant TP53. To support the clinical development of APR-246 it is important to understand its mechanism(s) of action. By establishing iso..

View full abstract

Grants

Awarded by Leukemia and Lymphoma Society


Funding Acknowledgements

This work was supported by funding from from the Victorian Cancer Agency Fellowship (MCRF 17028) awarded to G.L.K and (21006) awarded to STD, Cancer Council Victoria, grants-in-aid #1086157 and #1147328 awarded to GLK; the National Health and Medical Research Council, Project Grant #1086291 and Ideas grants #2002618 and #2001201 awarded to GLK, Program Grant #101671 awarded to AS and GL, Fellowships #1020363 awarded to AS, #1117089 awarded to GL, Investigator grant #2007887 awarded to AS; the Leukaemia and Lymphoma Society Grant #7015-18, awarded to AS, GLK and GL. the CASS Foundation (10151) to STD; the estate of Anthony (Toni) Redstone OAM awarded to GLK and AS and The Craig Perkins Cancer Research Foundation and the Dyson Bequest both awarded to GLK; and operational infrastructure grants through the Australian Government NHMRCS IRIISS and the Victorian State Government Operational Infrastructure Support.